Behind The Pledge - How EU money is spent for Covid19 drugs: How did we come to pay gold for a drug whose effectiveness has not been proven? This is the story of Remdesivir, a drug developed by the American company Gilead Sciences with large public funds to combat Ebola, and in July approved by the European Medicines Agency with "conditional authorisation" as the first antiviral against Covid 19.